Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

Three months Three months

ended Dec. 30, ended Dec. 30,

2007 2006

-----------------------------

Stock-based compensation expense (439) (799)

Termination and reorganization costs

related to facility consolidation

and integration activities (3,526) (1,879)

Litigation expenses relating to

defending intellectual property claims 291 (3,551)

---------------------------------------------------------------------

(3,674) (6,229)

---------------------------------------------------------------------

g. Amortization of acquisition related intangible assets and medical

technologies.

h. Non-recurring in-process research and development relating to

payments made to collaborators and licensors, including to

CombinatoRx Inc. and Rex Medical Inc., and a non-recurring license

termination payment of $125,000 to Lipose Corporation made in October

2007.

i. Foreign exchange fluctuations on foreign currency net monetary

assets.

j. Amortization of deferred financing costs.

k. Tax effects of adjustments for the period. Comparative for 2006 also

includes non-recurring retroactive tax adjustment of $8.7 million

relating to certain tax structures previously established in the

province of Quebec, from which the previously expected benefits are

not anticipated to be realized.

l. Loss on redemption of investments.

m. Loss on extinguishment of the term loans related to our December 2006

senior floating rate note refinancing.

n. Includes write off of AMI ta
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2Tropical birds waited for land crossing between North and South America: UBC study 2U S Debut 3A Holistic Health And Beauty From The Rainforest New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the Wo 51638 1U S Debut 3A Holistic Health And Beauty From The Rainforest New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the Wo 51638 2U S Debut 3A Holistic Health And Beauty From The Rainforest New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the Wo 51638 3CardioNet Terminates Merger With Biotel 51633 1Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 1Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 2Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 3Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 4Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 5Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 6Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 7Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 8Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 9